These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 1423301

  • 1. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
    Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR.
    Cancer Res; 1992 Dec 01; 52(23):6561-6. PubMed ID: 1423301
    [Abstract] [Full Text] [Related]

  • 2. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2.
    Rubin JT, Day R, Duquesnoy R, Simonis B, Adams S, Lee J, Lotze MT.
    Ther Immunol; 1995 Feb 01; 2(1):1-6. PubMed ID: 7553066
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [Abstract] [Full Text] [Related]

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    Clin Cancer Res; 2010 May 01; 16(9):2646-55. PubMed ID: 20406835
    [Abstract] [Full Text] [Related]

  • 8. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M, Rosenberg SA.
    Cancer Res; 1993 Aug 01; 53(15):3561-8. PubMed ID: 8101762
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX, Wang XY, Liu JB, Zhang SQ, Chen YR.
    Zhonghua Yi Xue Za Zhi; 2008 Apr 08; 88(14):973-6. PubMed ID: 18756970
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 08; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 15. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB.
    Cancer Res; 1993 Dec 01; 53(23):5654-62. PubMed ID: 8242620
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA.
    J Immunother (1991); 1991 Jun 01; 10(3):153-64. PubMed ID: 1868040
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A.
    J Pathol; 2008 Dec 01; 216(4):451-9. PubMed ID: 18798220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.